Related Experiment Video

Updated: Jun 20, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond

Rebecca H Ritchie1, Jennifer C Irvine, Anke C Rosenkranz

  • 1Heart Failure Pharmacology, Baker IDI Heart & Diabetes Institute Melbourne, Victoria, Australia. rebecca.ritchie@bakeridi.edu.au

Pharmacology & Therapeutics
|September 3, 2009
PubMed

Insights

Left ventricular hypertrophy (LVH) is a maladaptive cardiac remodeling. Cyclic guanosine monophosphate (cGMP) shows promise as an anti-hypertrophic mediator, offering new therapeutic avenues for managing LVH.

Area of Science:

  • Cardiovascular Medicine
  • Molecular Cardiology
  • Pharmacology

Background:

  • Left ventricular hypertrophy (LVH) is an adaptive response to cardiovascular stress that becomes maladaptive, leading to impaired cardiac function.
  • LVH is a significant predictor of cardiovascular morbidity and mortality, independent of blood pressure.
  • Current treatments for LVH primarily slow disease progression rather than induce reversal, highlighting the need for novel therapies.

Purpose of the Study:

  • To review the anti-hypertrophic actions of cyclic guanosine-3',5'-monophosphate (cGMP) in the heart.
  • To explore various methods of stimulating cardiac cGMP production, including natriuretic peptides.
  • To discuss the therapeutic potential of novel cGMP-based strategies for LVH management.

Main Methods:

  • Review of existing literature on cGMP signaling in cardiac hypertrophy.
  • Analysis of different pathways for cGMP stimulation in the heart.
  • Comparison of traditional nitric oxide (NO) donors with novel therapeutic alternatives.

Main Results:

  • cGMP is increasingly recognized as a key mediator against cardiac hypertrophy.
  • Novel approaches like NO siblings, soluble guanylyl cyclase (sGC) and particulate guanylyl cyclase (pGC) activators, and phosphodiesterase inhibitors offer potential advantages over traditional NO donors.
  • cGMP-based therapies demonstrate potential for innovative pharmacotherapy in LVH management.

Conclusions:

  • Stimulation of cardiac cGMP pathways represents a promising therapeutic strategy for reversing or managing LVH.
  • Novel cGMP-modulating agents may overcome limitations of current treatments.
  • cGMP-based therapies hold potential as standalone or adjunctive treatments for cardiovascular disorders characterized by LVH.

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...